After a period of volatility, the biopharma industry enters 2026 with cautious optimism. Companies are preparing for a major patent cliff by shifting toward disciplined growth, driven by tighter capital efficiency, more selective investment, and renewed momentum in mergers and acquisitions (M&A).
eBOOK | FEB 10, 2026
2026 Financing Outlook
The life sciences industry enters 2026 with cautious confidence. After two years of volatility, the sector has found its footing in an environment that rewards disciplined growth, sharper portfolio decisions and capital efficiency.
This report from In Vivo brings together data, insights and perspectives that provide clarity for innovators, dealmakers, pharma strategists and investors.
Complete the form to read more.
Why Download
See where biopharma funding is really flowing in 2026
Get a clear picture of how financing conditions are changing. Find out what’s coming back, what's still constrained, and which assets investors are backing.
Benchmark your strategy against industry leaders and active deal‑makers
Use our data‑driven analysis and league‑table insights to compare your financing, growth, and valuation projections against other biopharma and medtech.
Understand how financing connects to M&A, innovation, and long‑term growth
Go beyond the headlines to see how capital allocation links to patent risk, deal‑making, and innovation strategies.
FAQ
What is the overall outlook for biopharma in 2026?
Why is the upcoming patent cliff such a defining issue for biopharma companies?
Between 2025 and 2030, biopharma products generating roughly $300 billion in annual revenues are expected to lose exclusivity. This creates significant pressure on large pharma portfolios, pushing affected companies toward M&A, licensing, and innovation-driven strategies to replace at-risk revenues while also transforming competitive dynamics across the industry.
How are capital markets and fundraising conditions changing in 2026?
Investor sentiment has improved, equity valuations are more favorable, and public companies are raising capital more successfully through follow-on offerings, private investments in public equity (PIPEs), and debt. However, clinical-stage companies are attracting the most investor interest, while early-stage start-ups continue to face tighter access to capital.
What role is artificial intelligence playing in biopharma strategy?
AI is increasingly viewed as a strategic enabler across the biopharma value chain rather than a set of isolated use cases. While only a limited number of AI-designed drugs have reached mid-stage clinical trials, AI is already delivering value by accelerating R&D, improving decision-making, reducing costs, and enabling “smart pipelines” that combine human oversight with agentic AI systems.
Which big-cap companies are expected to perform best in 2026?
Insmed and Alnylam Pharmaceuticals stand out among big caps. Their projected growth is driven by recent FDA approvals, strong launch momentum, and expanding indications for key products.
Which big-cap companies are expected to struggle in 2026?
Bristol Myers Squibb and Otsuka Holdings are forecast to post sales declines largely linked to patent expirations, pricing pressure, and generic competition affecting major revenue generating products.
What are corporate venture capital investors looking for in pharmatech and digital health companies?
Corporate venture capitalists (VCs) prioritize companies with transformational technology, strong teams, strategic relevance, and independent, venture-backable business models. Revenue traction and product-market fit are increasingly critical, and founders must demonstrate clear milestones, capital efficiency, and the ability to succeed with or without a strategic partnership.
Explore the product behind the insights
